Second-line therapy for advanced colorectal cancer

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Advanced colorectal cancer (CRC) treatment has evolved significantly with the introduction of irinotecan and oxaliplatin.
• Biologic agents like bevacizumab and cetuximab further increase treatment complexity.

Purpose of the Study:

• To review randomized clinical trials on second-line treatment for advanced CRC.
• To evaluate treatment efficacy after failure of first-line therapies including 5-fluorouracil (5-FU), irinotecan, or oxaliplatin.

Main Methods:

• Systematic review of randomized clinical trials.
• Analysis of second-line treatment strategies in advanced colorectal cancer.

Main Results:

• Second-line chemotherapy is superior to best supportive care.
• Following 5-FU failure, irinotecan, FOLFIRI, FOLFOX, and IROX are effective, with IROX potentially superior to FOLFIRI.
• After irinotecan-based first-line therapy, FOLFOX is a preferred choice, with FOLFOX plus bevacizumab outperforming FOLFOX alone.
• For FOLFOX-pretreated patients, irinotecan and FOLFIRI are suitable options; irinotecan plus cetuximab shows promise.

Conclusions:

• Active chemotherapy regimens offer significant survival benefits over best supportive care in second-line treatment for advanced CRC.
• Treatment selection should be guided by prior first-line therapy, incorporating irinotecan, oxaliplatin, and biologic agents.
• Further research is needed to optimize the use of novel agents and combinations in advanced CRC management.